AMPH Amphastar Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMPH

Price (delayed)

$20.18

Market cap

$858.42M

P/E Ratio

11.6

Dividend/share

N/A

EPS

$1.74

Enterprise value

$1.32B

?
Relative Growth: Rel. Growth: 70
Relative Strength: Rel. Strength: 20
Relative Valuation: Rel. Valuation: 82
Relative Profitability: Rel. Profitability: 54

Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredients, or ...

Highlights
The stock's P/E is 27% less than its 5-year quarterly average of 15.9
The company's gross profit fell by 3.4% YoY but it rose by 2% QoQ
The net income has contracted by 42% YoY
The EPS has contracted by 38% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amphastar.com
Peers: SCYX

Key stats

What are the main financial stats of AMPH

AMPH stock price

How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
1%
1 week
1.87%
1 month
4.61%
1 year
-33.79%
YTD
-24.65%
QTD
0%

Financial performance

How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$730.02M
Gross profit
$348.11M
Operating income
$114.29M
Net income
$78.55M
Gross margin
47.7%
Net margin
10.8%
AMPH's net margin is down by 42% year-on-year
The net income has contracted by 42% YoY
The operating income has declined by 37% year-on-year and by 2.1% since the previous quarter
AMPH's operating margin is down by 37% year-on-year and by 3.1% since the previous quarter

Price vs fundamentals

How does AMPH's price correlate with its fundamentals

Growth

What is Amphastar Pharmaceuticals's growth rate over time

Valuation

What is Amphastar Pharmaceuticals stock price valuation
AMPH P/E details
P/E
11.6
P/B
1.16
P/S
1.21
EV/EBIT
10.32
EV/EBITDA
6.86
EV/Sales
1.81
The EPS has contracted by 38% YoY
The stock's P/E is 27% less than its 5-year quarterly average of 15.9
The price to book (P/B) is 57% lower than the 5-year quarterly average of 2.7 and 17% lower than the last 4 quarters average of 1.4
AMPH's price to sales (P/S) is 57% less than its 5-year quarterly average of 2.8 and 19% less than its last 4 quarters average of 1.5

Efficiency

How efficient is Amphastar Pharmaceuticals business performance
The company's return on assets fell by 45% YoY and by 2.1% QoQ
The ROE has contracted by 45% YoY
The ROIC is down by 35% year-on-year
The ROS has contracted by 32% YoY

Dividends

What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPH.

Financial health

How did Amphastar Pharmaceuticals financials performed over time
The total assets is 79% greater than the total liabilities
Amphastar Pharmaceuticals's current ratio has decreased by 38% from the previous quarter and by 27% YoY
Amphastar Pharmaceuticals's quick ratio has decreased by 38% QoQ and by 20% YoY
AMPH's debt is 10% smaller than its equity
AMPH's debt is up by 5% year-on-year
Amphastar Pharmaceuticals's debt to equity has increased by 3.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.